OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
2.900
-0.100 (-3.33%)
Apr 2, 2025, 11:31 AM EDT - Market open

OncoCyte Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
83402138200161
Upgrade
Market Cap Growth
94.02%94.02%-45.76%-80.98%24.52%37.45%
Upgrade
Enterprise Value
79411414162159
Upgrade
Last Close Price
3.002.382.506.4243.4047.80
Upgrade
PS Ratio
20.8521.3013.7439.7491.06132.18
Upgrade
PB Ratio
-6.85-3.260.810.963.074.80
Upgrade
P/TBV Ratio
-----17.31
Upgrade
EV/Sales Ratio
42.0621.649.6015.0773.75130.37
Upgrade
Debt / Equity Ratio
-0.30-0.300.110.090.090.26
Upgrade
Debt / EBITDA Ratio
0.010.010.00---
Upgrade
Asset Turnover
0.030.030.020.010.020.03
Upgrade
Quick Ratio
1.411.411.381.852.500.89
Upgrade
Current Ratio
1.621.621.492.112.771.03
Upgrade
Return on Equity (ROE)
-910.86%-910.86%-76.26%-35.52%-88.37%-93.07%
Upgrade
Return on Assets (ROA)
-26.42%-26.42%-15.91%-13.88%-13.82%-42.66%
Upgrade
Return on Capital (ROIC)
-146.37%-146.37%-38.88%-31.60%-26.30%-51.52%
Upgrade
Earnings Yield
-72.46%-151.40%-134.52%-191.48%-32.03%-18.62%
Upgrade
FCF Yield
-25.25%-52.98%-114.30%-131.09%-19.08%-16.93%
Upgrade
Buyback Yield / Dilution
-70.84%-70.84%-38.10%-24.61%-35.80%-27.65%
Upgrade
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q